A Gene Therapy Could Help a Child with Batten Disease — But Access Remains Elusive
Wheeler Stecker, diagnosed at four weeks old with CLN3-related Batten disease, has yet to receive an experimental gene therapy that could help preserve his vision. Despite early diagnosis and high-profile connections of his parents—former Trump administration officials—the family faces significant barriers in accessing the treatment due to clinical trial eligibility restrictions and financial limitations affecting drug development. The story highlights broader challenges in rare disease treatments: promising therapies often fail to reach patients because they are excluded from trials, companies struggle with funding or regulatory hurdles, and compassionate use requests raise ethical dilemmas. The Steckers' efforts underscore the gap between scientific progress and patient access, as their son's condition worsens. A company developing a potential treatment is in discussions with the FDA for possible pathways to help Wheeler before it’s too late.
Topics: Batten disease clinical trials access compassionate use FDA gene therapy